Liang Deng
16Patents
4h-index
17Co-inventors
49Inventor score
Filing activity: Jul 31, 2014 → Dec 21, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10736962B2 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Emerging Cross-Sectional Technologies | 13 | Active |
| US10548930B2 | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors | Chemistry; Metallurgy | 13 | Active |
| US10639366B2 | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | Chemistry; Metallurgy | 8 | Active |
| US10512662B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 4 | Active |
| US10176292B2 | STING crystals and modulators | Physics | 3 | Active |
| US11253560B2 | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors | Chemistry; Metallurgy | 2 | Active |
| US11285209B2 | Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Emerging Cross-Sectional Technologies | 2 | Active |
| US11541087B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US11986503B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US12036279B2 | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | Emerging Cross-Sectional Technologies | 1 | Active |
| US10765711B2 | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy | Chemistry; Metallurgy | 1 | Active |
| US11884939B2 | Vaccinia virus mutants useful for cancer immunotherapy | Chemistry; Metallurgy | 0 | Active |
| US12252702B2 | Recombinant poxviruses for cancer immunotherapy | Emerging Cross-Sectional Technologies | 0 | Active |
| US12397029B2 | Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors | Chemistry; Metallurgy | 0 | Active |
| US11242509B2 | Vaccinia virus mutants useful for cancer immunotherapy | Chemistry; Metallurgy | 0 | Active |
| US11426460B2 | Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.